{
  "id": 12525071,
  "title": "LEN won’t sell itself: 6 lessons from HIV prevention pills",
  "url": "https://urgent.news/2026/10/07/len-wont-sell-itself-6-lessons-from-hiv-prevention-pills",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-07T02:30:00.000Z",
  "source": {
    "name": "Bhekisisa",
    "slug": "bhekisisa",
    "url": "https://bhekisisa.org/opinion/2026-10-07-len-wont-sell-itself-6-lessons-from-hiv-prevention-pills/"
  },
  "original_language": "en",
  "account": "South Africa is set to roll out lenacapavir (LEN), an HIV prevention injection effective for six months, but successful uptake requires deliberate efforts. Despite being free and available at most government clinics, previous HIV prevention pills, such as oral PrEP, have seen low usage. In a study by Wits University's Health Economics and Epidemiology Office, personal contact proved most effective in getting people to start prevention medication, with 46-50% initiating it after hearing about it. To ensure LEN's success, South Africa must employ trusted messengers, make the injection easily accessible once people want it, budget for demand creation, and avoid promoting it in clinics with limited stock. By creating demand through deliberate efforts like community outreach and peer education, South Africa can maximize the potential of this highly effective HIV prevention medicine.",
  "summary": "South Africa has a twice-yearly HIV prevention jab that’s almost 100% effective. But experience with HIV prevention pills shows that making medicine free isn’t enough to get people to use it. Here are five lessons for making sure LEN reaches the people who need it. The post LEN won’t sell itself: 6 lessons from HIV prevention pills appeared first on Bhekisisa .",
  "key_points": [
    "Personal contact most effective in getting people to start LEN",
    "Trusted messengers, easy accessibility key to success",
    "Demand creation through community outreach and peer education"
  ],
  "editors_take": "South Africa's rollout of lenacapavir will likely mirror the low usage of previous HIV prevention pills unless the country employs targeted strategies to create demand and make the injection easily accessible.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}